← Browse by Condition
Medical Condition

hypogammaglobulinemia

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for hypogammaglobulinemia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hypogammaglobulinemia Clinical Trials

How many clinical trials are currently recruiting for hypogammaglobulinemia?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hypogammaglobulinemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hypogammaglobulinemia?
hypogammaglobulinemia research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hypogammaglobulinemia clinical trial?
Eligibility criteria for hypogammaglobulinemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Phase 3
1
Top Sponsors
Monash University 1 trial
Insel Gruppe AG, University Hospital Bern 1 trial
Memorial Sloan Kettering Cancer Center 1 trial

Recruiting Clinical Trials

NCT05678621 Phase 2, Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Enrollment
300 pts
Location
Australia
Sponsor
Monash University
View Trial →
NCT05357781
Recruiting
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
Enrollment
106 pts
Location
Switzerland
Sponsor
Insel Gruppe AG, University Ho...
View Trial →
NCT06976476 Phase 2
Recruiting
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Enrollment
100 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →

Related Conditions

haematological malignancy (1) multiple sclerosis (1) fatigue (1) multiple myeloma (1) hypogammaglobulinemia acquired (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology